Literature DB >> 20652821

Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone.

Daisuke Katagiri1, Maki Shibata, Takashi Katsuki, Shoichi Masumoto, Ai Katsuma, Eri Minami, Taro Hoshino, Tsuyoshi Inoue, Manami Tada, Fumihiko Hinoshita.   

Abstract

An elderly patient with pure red cell aplasia (PRCA) with antierythropoietin (anti-EPO) antibodies is described. PRCA due to alloimmunization is a rare and severe complication of recombinant human erythropoietin (rHu-EPO) therapy. Most reported patients with PRCA were cured primarily by immunosuppressive drug therapy. The patient in this case, however, did not want to receive any immunosuppressive drugs. Therefore, rHu-EPO injection was simply discontinued, the severe anemia gradually improved, and the hemoglobin approached normal range. This case is very rare and significant in that there have been few such elderly patients with rHu-EPO-induced PRCA in whom PRCA remission was achieved, with decreasing antibody titers, after cessation of rHu-EPO alone. Further cases are needed to assess how PRCA should be treated in patients with anti-EPO antibodies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652821     DOI: 10.1007/s10157-010-0318-8

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  15 in total

1.  Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

Authors:  Richard B Stead; John Lambert; Dawie Wessels; Julie S Iwashita; Kerstin K Leuther; Kathryn W Woodburn; Peter J Schatz; Douglas M Okamoto; Robert Naso; Anne-Marie Duliege
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

2.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

Authors:  Nicole Casadevall; Joelle Nataf; Beatrice Viron; Amir Kolta; Jean-Jacques Kiladjian; Philippe Martin-Dupont; Patrick Michaud; Thomas Papo; Valerie Ugo; Irene Teyssandier; Bruno Varet; Patrick Mayeux
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

3.  Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors:  Charles L Bennett; Denis Cournoyer; Kenneth R Carson; Jerome Rossert; Stefano Luminari; Andrew M Evens; Francesco Locatelli; Steven M Belknap; June M McKoy; E Alison Lyons; Benjamin Kim; Rishi Sharma; Stacey Costello; Edwin B Toffelmire; George A Wells; Hans A Messner; Paul R Yarnold; Steven M Trifilio; Dennis W Raisch; Timothy M Kuzel; Allen Nissenson; Lay-Cheng Lim; Martin S Tallman; Nicole Casadevall
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

4.  Autoantibodies against erythropoietin in a patient with pure red-cell aplasia.

Authors:  N Casadevall; E Dupuy; P Molho-Sabatier; G Tobelem; B Varet; P Mayeux
Journal:  N Engl J Med       Date:  1996-03-07       Impact factor: 91.245

Review 5.  Erythropoietin-induced, antibody-mediated pure red cell aplasia.

Authors:  Jérôme Rossert
Journal:  Eur J Clin Invest       Date:  2005-12       Impact factor: 4.686

6.  The effect of treatment with Campath-1H in patients with autoimmune cytopenias.

Authors:  F Willis; J C Marsh; D H Bevan; S B Killick; G Lucas; R Griffiths; W Ouwehand; G Hale; H Waldmann; E C Gordon-Smith
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

7.  Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia.

Authors:  M Zecca; P De Stefano; B Nobili; F Locatelli
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

8.  Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin.

Authors:  Steven J Swanson; John Ferbas; Patrick Mayeux; Nicole Casadevall
Journal:  Nephron Clin Pract       Date:  2004

9.  A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

Authors:  Iain C Macdougall; Jerome Rossert; Nicole Casadevall; Richard B Stead; Anne-Marie Duliege; Marc Froissart; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

10.  Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins.

Authors:  Gertrud Weber; Johann Gross; Arno Kromminga; Hans-H Loew; Kai-Uwe Eckardt
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

View more
  4 in total

1.  Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine.

Authors:  Keiji Hirai; Susumu Ookawara; Haruhisa Miyazawa; Kiyonori Ito; Yuichiro Ueda; Yoshio Kaku; Taro Hoshino; Shun-Ichi Kimura; Izumi Yoshida; Sachiko Kakuta; Yoshiyuki Morishita; Kaoru Tabei
Journal:  CEN Case Rep       Date:  2015-09-15

2.  Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with low-dose prednisolone.

Authors:  Kazunari Aoki; Yuichiro Ono; Sumie Tabata; Akiko Matsushita; Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2013-01-26       Impact factor: 2.490

3.  Post-production protein stability: trouble beyond the cell factory.

Authors:  Esther Vazquez; José Luis Corchero; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2011-08-01       Impact factor: 5.328

4.  Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.

Authors:  Yasuki Shingu; Tomohiro Nakata; Shinji Sawai; Hisaya Tanaka; Osamu Asai; Keiichi Tamagaki; Kimihiko Nakatani
Journal:  BMC Nephrol       Date:  2020-07-14       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.